Gene therapy for wet AMD: how do eyes hold up years later?

NCT ID NCT04645212

Ongoing Disease control Sponsor: Adverum Biotechnologies, Inc. Source: ClinicalTrials.gov ↗

First seen Feb 12, 2026 · Last updated May 24, 2026 · Updated 14 times

Summary

This study follows 23 people who received a single dose of ADVM-022 gene therapy for wet age-related macular degeneration (AMD). Researchers are checking long-term safety and whether vision improvements last. Participants are observed over time without receiving additional treatment in this study.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Adverum Clinical Site

Bakersfield, California, 93309, United States
Adverum Clinical Site

Beverly Hills, California, 90211, United States
Adverum Clinical Site

Lakewood, Colorado, 80228, United States
Adverum Clinical Site

Deerfield Beach, Florida, 33064, United States
Adverum Clinical Site

Reno, Nevada, 89502, United States
Adverum Clinical Site

Philadelphia, Pennsylvania, 19107, United States
Adverum Clinical Site

Nashville, Tennessee, 37203, United States
Adverum Clinical Site

Bellaire, Texas, 77401, United States
Adverum Clinical Site

The Woodlands, Texas, 77384, United States

Conditions

Explore the condition pages connected to this study.

NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WET AGE RELATED MACULAR DEGENERATION